BQPrime
•Natco Pharma Q2 Results Review - Strong Growth On Low Base; Weak Q3 Expected: Nirmal Bang
73% Informative
Revenue grew by ~139% YoY, on account of a low base in th Ebitda rt business and ramp up in crop protection business led by calculated total peripheral resistance. India Gi">Original DISCLAIMER Revlimid Nirmal Bang Report 7 Natco Pharma Ltd. lass="summaryFeed_highLightText__NxlGi">Rs 28.5 Ebitda Feed_highLightText__NxlGi">September YoY an class="summaryFeed_highLightText__NxlGi">24 Rs 861 Nat ~10% h YoY a 180% g YoY ghtText__N Revlimid cumulate 44.4% d_highLightText_ Revlimid U.S. Natco Pharma _NxlGi">U.S. Revlimid xlGi">two
VR Score
76
Informative language
77
Neutral language
68
Article tone
formal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links